Genomic Tool, Dx Stocks Outperformed Pharma, Biotech in December, Report Shows

Jan 07, 2005

NEW YORK, Dec. 7 (GenomeWeb News) - Shares in genomic-based diagnostics and tools companies outperformed big drug makers and firms in other healthcare industry segments, according to a Pacific Growth Equities report analyzing stocks in the healthcare industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Main menu